ArticleHealth economics review2014
Pharmaceutical regulation in Europe and its impact on corporate R&D.
Article in Health economics review, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Affordable Prices Without Threatening the Oncological R&D Pipeline-An Economic Experiment on Transparency in Price Negotiations.Cancer research communications · 2022Trial
- The impact of the United States most favored nation policies on prices of branded medicines and research and development.Health policy OPEN · 2026Review
- Impact of China's national drug price negotiation on pharmaceutical firms' innovation activities.Frontiers in public health · 2026Article
- Impact of national volume-based procurement reform on the markup of pharmaceutical firms: an event study.Cost effectiveness and resource allocation : C/E · 2025Article
- The impact of centralized band purchasing of pharmaceuticals on innovation of Chinese pharmaceutical firms: an empirical study based on double difference models.Frontiers in public health · 2024Article
- Medicines prices in International (Geary-Khamis) Dollar. The comparison between regulated and deregulated markets.PloS one · 2024Article
- Machine learning analysis of patients' perceptions towards generic medication in Greece: a survey-based study.Frontiers in drug safety and regulation · 2024Article
- Pharma 4.0: analysis on core competence and digital levelling implementation in pharmaceutical industry in Indonesia.Heliyon · 2022Article
- Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment.Applied health economics and health policy · 2021Article
- Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis.Health economics review · 2021Article
- Language Bias in Health Research: External Factors That Influence Latent Language Patterns.Frontiers in research metrics and analytics · 2020Article
- Health care's ills: A Catholic diagnosis.The Linacre quarterly · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMany European countries regulate the markets for prescription drugs in order to cope with rising health expenditures. On the other hand, regulation distorts incentives to invest in pharmaceutical R&D. This study aims at empirically assessing the impact of regulation on pharmaceutical R&D expenditures.
methodsWe analyze a sample of 20 leading pharmaceutical companies between 2000 and 2008. The share of sales in Europe serves as a proxy for the degree of pharmaceutical regulation. We control for other firm specific determinants of R&D such as cash flow, company size, leverage ratio, growth rate, and Tobin's q.
resultsOur results suggest a nonlinear relationship between European sales ratio and R&D intensity. Beyond a threshold of 33% of sales generated in Europe, a higher presence in Europe is associated with lower R&D investments.
conclusionThe results can be interpreted as further evidence of the deteriorating effect of regulation on firm's incentives to invest in R&D.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.